Back to Dashboard

R1979-HM-2299 (Olympia-4)

Lymphoma•NCT06230224•Last updated: 2/17/2026
Recruiting

Study Design

Study Drug

Odronextamab

Mechanism of Action

CD20+CD3 bispecific Ab

Sponsor

Unknown

Design

III

Control Arm

R-ICE R-DHAP R-GDP

Criteria

Inclusion Criteria

1. DLBCL(de novo or transformed indolent NHL, high-grade B with MYC+BCL2 ± BCL6 2. r/r within 12m from 1st treatment

Age: Phase: III

Exclusion Criteria

Enrollment

Progress1 / 3

Contact Information

Principal Investigator

Unknown

Study Nurse

劉璟穎

Contact Tel

6452